Results 21 to 30 of about 42,124 (246)
Autophagy and Tamoxifen Resistance in Breast Cancer.
Cancer Research, 2009 Abstract Resistance totamoxifen in breast cancer patients is a serious therapeutic problem and majorefforts are underway to understand underlying mechanisms. Resistance can be either intrinsic or acquired. We derived matched tamoxifen sensitive and resistant MCF7 sub-clones that allow us to ask what changes occur in a breast cancer cell ...
L. Gonzalez-Malerva +7 more
openaire +2 more sources
Frontiers in Oncology, 2022 Acquired resistance is a major clinical challenge for tamoxifen-based therapy. In this study, we focused on lncRNA SNHG6 which plays a role in chemoresistance of cancer cells, but has never been investigated in the context of tamoxifen resistance.
Mohammad Imran Khan +2 more
doaj +1 more source
Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine [PDF]
Integrative Cancer Therapies, 2021 Background: Tamoxifen is one of the medicines for adjuvant endocrine therapy of hormone-dependent breast cancer. However, development of resistance to tamoxifen occurs inevitably during treatment. This study aimed to determine whether sensitivity of tamoxifen-resistant breast cancer cells (TAM-R) could be ...
Yuntao Wang +5 more
openaire +3 more sources
Mechanisms of tamoxifen resistance [PDF]
Endocrine-Related Cancer, 2004 The anti-oestrogen tamoxifen is the most commonly used treatment for patients with oestrogen-receptor (ER)-positive breast cancer. Although many patients benefit from tamoxifen in the adjuvant and metastatic settings, resistance is an important clinical problem. The target of tamoxifen in vivo is the ER.
Alistair, Ring, Mitch, Dowsett
openaire +2 more sources
Pathways to tamoxifen resistance [PDF]
Cancer Letters, 2007 Therapies that target the synthesis of estrogen or the function of estrogen receptor(s) have been developed to treat breast cancer. While these approaches have proven to be beneficial to a large number of patients, both de novo and acquired resistance to these drugs is a significant problem.
Rebecca B, Riggins +3 more
openaire +2 more sources
Clonal selection in tamoxifen resistance [PDF]
Cancer Biology & Therapy, 2010 Commentary to:MCF-7 breast cancer cells selected for tamoxifen resistance acquire new phenotypes differing in DNA content, phospho-HER2 and PAX2 expression, and rapamycin sensitivityEuphemia Leung, Nagarajan Kannan, Geoffrey W. Krissansen, Michael P.
Kideok, Jin, Saraswati, Sukumar
openaire +2 more sources
NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
Cells, 2021 Endocrine therapy is used to treat estrogen receptor (ER)-positive breast cancer. Tamoxifen is effective against this cancer subtype. Nonetheless, approximately 30% of patients treated with tamoxifen acquire resistance, resulting in therapeutic ...
Yu Cheon Kim +3 more
doaj +1 more source
PRODH Regulates Tamoxifen Resistance through Ferroptosis in Breast Cancer Cells. [PDF]
Genes (Basel)Background: Estrogen receptor-positive breast cancer accounts for around 70% of all cases. Tamoxifen, an anti-estrogenic inhibitor, is the primary drug used for this type of breast cancer treatment.
Zhang P +8 more
europepmc +2 more sources
Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells [PDF]
BMC Cancer, 2021 Abstract Background The mechanisms of endocrine resistance are complex, and deregulation of several oncogenic signalling pathways has been proposed. We aimed to investigate the role of the EGFR and Src-mediated STAT3 signalling pathway in tamoxifen-resistant breast cancer cells. Methods
Seo Yun Moon +9 more
openaire +3 more sources
Cancer Medicine, 2020 Tamoxifen‐based hormone therapy is central for the treatment of estrogen receptor positive (ER+) breast cancer. However, the acquired tamoxifen resistance, typically co‐exists with hypoxia, remains a major challenge.
Ying Li +10 more
doaj +1 more source